异位性皮肤炎治疗市场：市场机会、成长要素、产业趋势分析及2026-2035年预测

2025 年全球异位性皮肤炎治疗市场价值 132 亿美元，预计到 2035 年将达到 344 亿美元，年复合成长率为 10.1%。

异位性皮肤炎治疗市场正经历强劲成长，这主要得益于这种慢性发炎性皮肤病在全球日益普遍的盛行率以及创新治疗方法的快速发展。异位性皮肤炎持续影响越来越多的儿童和成人患者，因此对有效、长期的治疗方案的需求也持续成长。製药公司正积极投资研发，以推出能够改善症状控制和疾病管理的先进治疗方法。皮肤科治疗领域的持续创新拓宽了可用的治疗方法范围，使医生能够根据每位患者的个别需求制定治疗策略。此外，新型局部和全身疗法的出现正在改变轻度、中度和重度异位性皮肤炎的治疗框架。随着这些新治疗方法在临床实践中广受认可，并在真实临床环境中展现出良好的长期疗效，其应用范围也不断扩大。多样化的治疗类别和给药途径的日益丰富度正在增强治疗格局，预计将在未来几年内支撑异位性皮肤炎治疗市场的持续成长。

异位性皮肤炎药物是专门用于控制异位性皮肤炎症状和延缓其进展的药物。异位性皮肤炎是一种慢性皮肤病，其特征是发炎、持续性搔痒和干燥。这些药物旨在减轻发炎反应，缓解症状加重带来的不适，并长期维持皮肤健康。治疗方案旨在透过标靶治疗机制来控制症状、预防疾病復发和进行长期疾病管理。

到2025年，生物製剂将占据41.4%的市场。生物製剂疗法是中重度异位性皮肤炎患者的重要治疗选择，因为它们能够针对与疾病相关的特定发炎路径进行高度标靶干预。这些疗法透过选择性地调节参与慢性发炎的关键免疫讯号分子来发挥作用。因此，生物製药可以实现持续的症状控制，减少疾病復发，并显着改善皮肤健康和患者的生活品质。与广泛抑制免疫系统不同，生物製剂能够精准靶向发炎的分子因子，从而提高临床疗效，同时确保需要长期治疗的患者的安全性。

预计到2025年，注射剂市占率将达到45.2%。该领域的成长与先进注射疗法的日益普及密切相关，这些疗法专注于调节疾病进展中涉及的特定发炎路径。标靶治疗方案的扩展显着促进了中度至重度症状患者对注射剂的接受度。此外，主要医药市场的监管机构已核准多种注射疗法用于治疗异位性皮肤炎。这些监管核准正在加速新治疗方法在临床实践中的应用，为医疗专业人员提供更广泛的有效治疗选择，并促进整个医疗系统的普及。

预计到2025年，北美异位性皮肤炎治疗市场将占据显着份额。该地区凭藉其先进的皮肤科医疗基础设施、便捷获取最新治疗方案以及创新治疗方法（包括生物製药和靶向免疫调节药物）的快速引入，保持着强劲的全部区域地位。完善的法规结构确保了新皮肤科治疗方法的评估和核准的一致性，同时维持了高标准的临床安全性。支撑该地区市场主导地位的关键因素之一是异位性皮肤炎在人群中的高发病率，这持续推动对先进治疗方案的需求。中重度患者越来越倾向于寻求能够更有效地控制症状和进行长期疾病管理的全新治疗方案，这进一步增强了该地区的市场前景。

目录

第一章：调查方法

• 研究途径
• 品质改进计划
  • GMI人工智慧政策和资料完整性倡议
    • 资讯来源一致性通讯协定
• 调查过程和可靠性评分
  • 调查过程的组成部分
  • 评分组成部分
• 数据收集
  • 主要来源部分列表
• 资料探勘资讯来源
  • 付费资讯来源
    • 区域资讯来源
• 基本估算和计算方法
  • 每种方法中基准年的计算
• 预测模型
  • 量化市场影响分析
    • 生长参数对预测的数学影响
• 关于调查透明度的补充信息
  • 资讯来源归属框架
  • 品质保证指标
  • 对信任的承诺

第二章执行摘要

第三章业界考察

• 生态系分析
• 影响产业的因素
  • 促进因素
    • 异位性皮肤炎盛行率增加
    • 生物製药治疗的进展
    • 提高对皮肤病护理的认识和获取途径
    • 加强临床试验流程
  • 产业潜在风险与挑战
    • 生物製药和先进治疗方法高成本
    • 副作用和用药依从性问题
  • 市场机会
    • 局部用药的创新和非类固醇疗法的扩展
• 成长潜力分析
• 监理情势
• 技术趋势（基于初步调查）
  • 目前技术
  • 新兴技术
• 未来市场趋势（基于初步研究）
• 管道分析（基于初步调查）
• 人工智慧和生成式人工智慧对市场的影响
• 波特五力分析
• PESTEL 分析

第四章 竞争情势

• 介绍
• 企业市占率分析
• 企业矩阵分析
• 主要市场公司的竞争分析
• 竞争定位矩阵
• 主要进展
  • 併购
  • 伙伴关係与合作
  • 新产品发布
  • 业务拓展计划

第五章 市场估计与预测：依药物类别划分，2022-2035年

• 皮质类固醇
• Calcineurin抑制剂
• 生物製药
• 磷酸二酯酶-4 (PDE-4) 抑制剂
• 其他药物分类

第六章 市场估计与预测：依给药途径划分，2022-2035年

• 外用
• 口服
• 注射药物

第七章 市场估计与预测：依病患群体划分，2022-2035年

• 儿童
• 成人

第八章 市场估算与预测：依通路划分，2022-2035年

• 医院药房
• 零售药房
• 电子商务

第九章 市场估计与预测：依地区划分，2022-2035年

• 北美洲
  • 我们
  • 加拿大
• 欧洲
  • 德国
  • 英国
  • 法国
  • 西班牙
  • 义大利
  • 荷兰
• 亚太地区
  • 中国
  • 日本
  • 印度
  • 澳洲
  • 韩国
• 拉丁美洲
  • 巴西
  • 墨西哥
  • 阿根廷
• 中东和非洲
  • 南非
  • 沙乌地阿拉伯
  • 阿拉伯聯合大公国

第十章：公司简介

• AbbVie
• Arcutis Biotherapeutics
• Chugai Pharmaceutical
• Eli Lilly and Company
• Galderma Laboratories
• Incyte Corporation
• Leo Pharma
• Maruho
• Otsuka Pharmaceutical
• Pfizer
• Sanofi
• Viatris

The Global Atopic Dermatitis Drugs Market was valued at USD 13.2 billion in 2025 and is estimated to grow at a CAGR of 10.1% to reach USD 34.4 billion by 2035.

The market for atopic dermatitis therapeutics is experiencing strong expansion, largely driven by the increasing global prevalence of this chronic inflammatory skin disorder and the rapid development of innovative treatment options. Atopic dermatitis continues to affect a growing number of individuals across both pediatric and adult populations, creating sustained demand for effective long-term treatment solutions. Pharmaceutical companies are actively investing in research and development to introduce advanced therapies capable of delivering improved symptom control and disease management. Continuous innovation in dermatology treatments is expanding the range of available therapeutic approaches, allowing physicians to tailor treatment strategies to individual patient needs. In addition, emerging topical and systemic therapies are contributing to the transformation of treatment frameworks for mild, moderate, and severe disease stages. As new therapies gain wider clinical acceptance and demonstrate favorable long-term outcomes in real-world use, their adoption continues to increase. The growing availability of diverse treatment classes and administration routes is helping to strengthen the therapeutic landscape and is expected to support sustained growth in the atopic dermatitis drugs market over the coming years.

Atopic dermatitis drugs are pharmaceutical therapies developed to manage the symptoms and progression of atopic dermatitis, a chronic skin condition characterized by inflammation, persistent itching, and dryness. These medications aim to reduce inflammatory responses, relieve discomfort associated with flare-ups, and help maintain a healthy skin condition over time. Treatment approaches are designed to control symptoms, prevent disease recurrence, and support long-term disease management through targeted therapeutic mechanisms.

The biologics segment held a 41.4% share in 2025. Biologic therapies have become an important treatment option for patients experiencing moderate to severe disease conditions because they provide highly targeted intervention within specific inflammatory pathways associated with atopic dermatitis. These therapies act by selectively regulating key immune signaling molecules that contribute to chronic inflammation. As a result, biologics can deliver sustained symptom control, reduce the frequency of disease flare-ups, and significantly improve skin health and patient quality of life. Their ability to target precise molecular drivers of inflammation rather than suppressing the immune system broadly has strengthened their clinical effectiveness while supporting favorable long-term safety outcomes for patients requiring ongoing treatment.

The injectable segment generated 45.2% share in 2025. Growth in this segment is closely linked to the increasing availability of advanced injectable therapies that focus on regulating specific inflammatory pathways involved in disease progression. The expansion of targeted treatment options has contributed significantly to the adoption of injectable medications for patients with moderate to severe forms of the condition. In addition, regulatory authorities across major pharmaceutical markets have granted approvals for several injectable therapies intended for the management of atopic dermatitis. These regulatory approvals have accelerated the introduction of new treatments into clinical practice, allowing healthcare providers to access a broader selection of effective therapeutic solutions and increasing adoption across healthcare systems.

North America Atopic Dermatitis Drugs Market held a significant share in 2025. The region maintains a strong position due to its advanced dermatology care infrastructure, high accessibility to modern treatment options, and rapid adoption of innovative therapies, including biologics and targeted immunomodulatory medications. Well-established regulatory frameworks across the region ensure consistent evaluation and approval of new dermatology therapies while maintaining high clinical safety standards. A major factor supporting regional market leadership is the substantial prevalence of atopic dermatitis among the population, which continues to drive demand for advanced treatment solutions. Patients experiencing moderate to severe disease conditions are increasingly seeking newer therapeutic options capable of providing more effective symptom control and long-term disease management, further strengthening the regional market outlook.

Prominent companies operating in the Global Atopic Dermatitis Drugs Market include Sanofi, Pfizer, AbbVie, Eli Lilly and Company, Leo Pharma, Galderma Laboratories, Incyte Corporation, Otsuka Pharmaceutical, Maruho, Arcutis Biotherapeutics, Chugai Pharmaceutical, and Viatris. Companies competing in the Global Atopic Dermatitis Drugs Market are adopting multiple strategic initiatives to reinforce their market presence and strengthen competitive positioning. Major pharmaceutical manufacturers are prioritizing extensive research and development efforts aimed at discovering innovative therapies that target specific immune pathways associated with inflammatory skin diseases. Many organizations are also investing in the development of advanced biologic treatments, targeted immunomodulators, and improved topical formulations to enhance therapeutic effectiveness and patient outcomes. Strategic collaborations with biotechnology firms and research institutions are accelerating drug discovery and clinical development activities. In addition, companies are expanding their product pipelines, pursuing regulatory approvals across global markets, and strengthening commercial distribution networks. Continuous investment in clinical trials, technological innovation, and global market expansion remains essential for sustaining long-term growth within the atopic dermatitis drugs market.

Table of Contents

Chapter 1 Research Methodology

• 1.1 Research approach
• 1.2 Quality commitments
  • 1.2.1 GMI AI policy & data integrity commitment
    • 1.2.1.1 Source consistency protocol
• 1.3 Research trail & confidence scoring
  • 1.3.1 Research trail components
  • 1.3.2 Scoring components
• 1.4 Data collection
  • 1.4.1 Partial list of primary sources
• 1.5 Data mining sources
  • 1.5.1 Paid sources
    • 1.5.1.1 Sources, by region
• 1.6 Base estimates and calculations
  • 1.6.1 Base year calculation for any one approach
• 1.7 Forecast model
  • 1.7.1 Quantified market impact analysis
    • 1.7.1.1 Mathematical impact of growth parameters on forecast
• 1.8 Research transparency addendum
  • 1.8.1 Source attribution framework
  • 1.8.2 Quality assurance metrics
  • 1.8.3 Our commitment to trust

Chapter 2 Executive Summary

• 2.1 Industry 360° synopsis
• 2.2 Key market trends
  • 2.2.1 Drug class trends
  • 2.2.2 Route of administration trends
  • 2.2.3 Patient demographics trends
  • 2.2.4 Distribution channel trends
• 2.3 CXO perspectives: Strategic imperatives

Chapter 3 Industry Insights

• 3.1 Industry ecosystem analysis
• 3.2 Industry impact forces
  • 3.2.1 Growth drivers
    • 3.2.1.1 Rising prevalence of atopic dermatitis
    • 3.2.1.2 Advancements in biologic therapies
    • 3.2.1.3 Growing awareness and access to dermatological care
    • 3.2.1.4 Strengthening clinical pipeline
  • 3.2.2 Industry pitfalls and challenges
    • 3.2.2.1 High cost of biologic and advanced therapies
    • 3.2.2.2 Side effects and compliance issues
  • 3.2.3 Market opportunity
    • 3.2.3.1 Expansion of topical innovation and non-steroidal therapies
• 3.3 Growth potential analysis
• 3.4 Regulatory landscape
• 3.5 Technological landscape (Driven by Primary Research)
  • 3.5.1 Current technologies
  • 3.5.2 Emerging technologies
• 3.6 Future market trends (Driven by Primary Research)
• 3.7 Pipeline analysis (Driven by Primary Research)
• 3.8 Impact of AI and generative AI on the market
• 3.9 Porter's analysis
• 3.10 PESTEL analysis

Chapter 4 Competitive Landscape, 2025

• 4.1 Introduction
• 4.2 Company market share analysis
• 4.3 Company matrix analysis
• 4.4 Competitive analysis of major market players
• 4.5 Competitive positioning matrix
• 4.6 Key developments
  • 4.6.1 Merger and acquisition
  • 4.6.2 Partnership and collaboration
  • 4.6.3 New product launches
  • 4.6.4 Expansion plans

Chapter 5 Market Estimates and Forecast, By Drug Class, 2022 - 2035 ($ Bn)

• 5.1 Key trends
• 5.2 Corticosteroids
• 5.3 Calcineurin inhibitors
• 5.4 Biologics
• 5.5 Phosphodiesterase-4 (PDE-4) inhibitors
• 5.6 Other drug classes

Chapter 6 Market Estimates and Forecast, By Route of Administration, 2022 - 2035 ($ Bn)

• 6.1 Key trends
• 6.2 Topical
• 6.3 Oral
• 6.4 Injectable

Chapter 7 Market Estimates and Forecast, By Patient Demographics, 2022 - 2035 ($ Bn)

• 7.1 Key trends
• 7.2 Pediatric
• 7.3 Adults

Chapter 8 Market Estimates and Forecast, By Distribution Channel, 2022 - 2035 ($ Bn)

• 8.1 Key trends
• 8.2 Hospital pharmacies
• 8.3 Retail pharmacies
• 8.4 E-commerce

Chapter 9 Market Estimates and Forecast, By Region, 2022 - 2035 ($ Bn)

• 9.1 Key trends
• 9.2 North America
  • 9.2.1 U.S.
  • 9.2.2 Canada
• 9.3 Europe
  • 9.3.1 Germany
  • 9.3.2 UK
  • 9.3.3 France
  • 9.3.4 Spain
  • 9.3.5 Italy
  • 9.3.6 Netherlands
• 9.4 Asia Pacific
  • 9.4.1 China
  • 9.4.2 Japan
  • 9.4.3 India
  • 9.4.4 Australia
  • 9.4.5 South Korea
• 9.5 Latin America
  • 9.5.1 Brazil
  • 9.5.2 Mexico
  • 9.5.3 Argentina
• 9.6 Middle East and Africa
  • 9.6.1 South Africa
  • 9.6.2 Saudi Arabia
  • 9.6.3 UAE

Chapter 10 Company Profiles

• 10.1 AbbVie
• 10.2 Arcutis Biotherapeutics
• 10.3 Chugai Pharmaceutical
• 10.4 Eli Lilly and Company
• 10.5 Galderma Laboratories
• 10.6 Incyte Corporation
• 10.7 Leo Pharma
• 10.8 Maruho
• 10.9 Otsuka Pharmaceutical
• 10.10 Pfizer
• 10.11 Sanofi
• 10.12 Viatris